These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29698957)

  • 101. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
    Sequist LV; Joshi VA; Jänne PA; Muzikansky A; Fidias P; Meyerson M; Haber DA; Kucherlapati R; Johnson BE; Lynch TJ
    Oncologist; 2007 Jan; 12(1):90-8. PubMed ID: 17285735
    [TBL] [Abstract][Full Text] [Related]  

  • 102. [Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].
    Wang Y; Zhang XR; Zhu HX; Wang B; Xu NZ; Sun Y
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3069-73. PubMed ID: 18261354
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
    Lin CC; Yang JC
    Drugs; 2011 Jan; 71(1):79-88. PubMed ID: 21175241
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
    Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
    Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
    Tamura T; Kato Y; Ohashi K; Ninomiya K; Makimoto G; Gotoda H; Kubo T; Ichihara E; Tanaka T; Ichimura K; Maeda Y; Hotta K; Kiura K
    Biochem Biophys Res Commun; 2018 Jan; 495(1):360-367. PubMed ID: 29101033
    [TBL] [Abstract][Full Text] [Related]  

  • 106. [Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for lung adenocarcinoma].
    Miyamoto S; Ohkuma Y; Takagi Y; Shimokawa T; Hosomi Y; Iguchi M; Okamura T; Shibuya M
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1907-11. PubMed ID: 20948254
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.
    Li X; Cai W; Yang G; Su C; Ren S; Zhao C; Hu R; Chen X; Gao G; Guo Z; Li W; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 Sep; 12(9):1388-1397. PubMed ID: 28624467
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced
    Ortega-Granados AL; Artal-Cortes Á; Aguiar-Bujanda D; Oramas J; Fírvida JL; DE Castro J; Fuentes JC; Gordo R; Galán R; Trigo J;
    Anticancer Res; 2019 Mar; 39(3):1317-1328. PubMed ID: 30842164
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
    Zhou S; Hu X; Wang Y; Li J; Zhou L; Hao X; Liu Y; Shi Y
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):166-171. PubMed ID: 30311393
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
    Clark GM; Zborowski DM; Santabarbara P; Ding K; Whitehead M; Seymour L; Shepherd FA;
    Clin Lung Cancer; 2006 May; 7(6):389-94. PubMed ID: 16800964
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
    Lin GN; Peng JW; Liu PP; Liu DY; Xiao JJ; Chen XQ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e189-e194. PubMed ID: 25359280
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
    Erdogan B; Kodaz H; Karabulut S; Cinkaya A; Tozkir H; Tanriverdi O; Cabuk D; Hacioglu MB; Turkmen E; Hacibekiroglu I; Uzunoglu S; Cicin I
    Bosn J Basic Med Sci; 2016 Nov; 16(4):280-285. PubMed ID: 27371767
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
    Matam K; Goud I; Lakshmi M AM; Ravi V; Sridhar K; Vijayanand PR; Chakravarthy S; Prasad SV; Tabassum SN; Shaik NA; Syed R; Alharbi KK; Khan IA
    Asian Pac J Cancer Prev; 2015; 16(16):7071-6. PubMed ID: 26514492
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
    Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
    Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
    [TBL] [Abstract][Full Text] [Related]  

  • 115. EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.
    Zhang X; Zhang Y; Tang H; He J
    J Investig Med; 2017 Jan; 65(1):72-81. PubMed ID: 27664271
    [TBL] [Abstract][Full Text] [Related]  

  • 116. [The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].
    Yamaoka T; Ohmori T
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):857-62. PubMed ID: 22705678
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review.
    Mitchell P; Mok T; Barraclough H; Strizek A; Lew R; van Kooten M
    Clin Lung Cancer; 2012 Jul; 13(4):239-51. PubMed ID: 22154074
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
    Song Z; Lin B; Shao L; Zhang Y
    J Chin Med Assoc; 2013 Sep; 76(9):481-5. PubMed ID: 23769878
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
    Peng L; Song ZG; Jiao SC
    Sci Rep; 2014 Aug; 4():6104. PubMed ID: 25130612
    [TBL] [Abstract][Full Text] [Related]  

  • 120. [Erlotinib in non-small cell lung cancer].
    Takeda M; Okamoto I
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.